VEGFA and macular retinal edema: However, these fundamental clinically driven discoveries led to the development of bevacizumab and other anti-VEGFA agents, which are now the gold standard of care for the treatment of vascular pathologies of the eye, including the wet form of age-related macular degeneration, macular edema, and proliferative retinopathy associated with diabetes.